An overview of mortality & predictors of small-cell and non-small cell lung cancer among Saudi patients

被引:23
|
作者
Alghamdi, Hatim I. [1 ]
Alshehri, Ali F. [1 ]
Farhat, Ghada N. [2 ]
机构
[1] Minist Hlth, Riyadh, Saudi Arabia
[2] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA
关键词
MAJOR HISTOLOGICAL TYPES; PROGNOSTIC-FACTORS; CIGARETTE-SMOKING; CLASSIFICATION; EPIDEMIOLOGY; SURVIVAL; DISEASE; HEALTH; IMPACT; TUMORS;
D O I
10.1016/j.jegh.2017.09.004
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Lung cancer ranks as the top cancer worldwide in terms of incidence and constitutes a major health problem. About 90% of lung cancer cases are diagnosed at advance stage where treatment is not available. Despite evidence that lung cancer screening improves survival, guidelines for lung cancer screening are still a subject for debate. In Saudi Arabia, only 14% of lung cancers are diagnosed at early stage and researches on survival and its predictors are lacking. This overview analysis was conducted on predictors of lung cancer mortality according to the two major cancer types, small-cell lung cancers (SCLCs) and non-small cell lung cancers (NSCLCs) in Saudi Arabia. A secondary data analysis was performed on small-cell lung cancers (SCLCs) and Non-small cell lung cancers (NSCLCs) registered in the Saudi Cancer Registry (SCR) for the period 2009-2013 to estimate predictors of mortality for both lung cancer types. A total of 404 cases (197 SCLC and 207 NSCLC) were included in the analysis, all Saudi nationals. A total of 213 (52.75%) deaths occurred among lung cancer patients, 108 (54.82%) among SCLCs and 105 (50.72%) among NCSLCs. Three quarter of patients are diagnosis with advance stage for both SCLC & NSCLC. Univariate analysis revealed higher mean age at diagnosis in dead patients compared to alive patients for SCLCs (p = 0.04); but not NSCLCs, a lower mortality for NSCLCs diagnosed in 2013 (p = 0.025) and a significant difference in stage of tumor (p = 0.006) and (p = 0.035) for both SCLC and NSCLC respectively. In multiple logistic regression, stage of tumor was a strong predictor of mortality, where distant metastasis increased morality by 6-fold (OR = 5.87, 95% CI: 2.01 - 17.19) in SCLC and by 3-fold (OR = 3.29, 95% CI: 1.22 - 8.85) in NSCLC, compared to localized tumors. Those with NSCLC who were diagnosed in 2013 were less likely to die by 64% compared to NSCLC diagnosed in 2009 (OR = 0.36, 95% CI: 0.14 - 0.93). Age, sex, topography and laterality were not associated with mortality for both types of lung cancer. We observed that the stage of the tumor is the strongest predictor of mortality for both SCLCs and NSCLs. This confirms the impact of diagnostic stage on survival. However, establishing Saudi-specific lung cancer screening guidelines will require further research on the benefits and harms of screening modalities in the Saudi population. (C) 2017 Ministry of Health, Saudi Arabia. Published by Elsevier Ltd.
引用
收藏
页码:S1 / S6
页数:6
相关论文
共 50 条
  • [31] Molecular profiling of non-small cell lung cancer
    Forsythe, Marika L.
    Alwithenani, Akram
    Bethune, Drew
    Castonguay, Mathieu
    Drucker, Arik
    Flowerdew, Gordon
    French, Daniel
    Fris, John
    Greer, Wenda
    Henteleff, Harry
    MacNeil, Mary
    Marignani, Paola
    Morzycki, Wojciech
    Plourde, Madeleine
    Snow, Stephanie
    Xu, Zhaolin
    PLOS ONE, 2020, 15 (08):
  • [32] Outcome of Stereotactic Radiosurgery for Patients with Non-Small Cell Lung Cancer Metastatic to The Brain
    Mariya, Yasushi
    Sekizawa, Genichirou
    Matsuoka, Yoshisuke
    Seki, Hirobumi
    Sugawara, Takayuki
    JOURNAL OF RADIATION RESEARCH, 2010, 51 (03) : 333 - 342
  • [33] Trends in incidence and associated risk factors of suicide mortality in patients with non-small cell lung cancer
    Zhou, Huaqiang
    Xian, Wei
    Zhang, Yaxiong
    Chen, Gang
    Zhao, Shen
    Chen, Xi
    Zhang, Zhonghan
    Shen, Jiayi
    Hong, Shaodong
    Huang, Yan
    Zhang, Li
    CANCER MEDICINE, 2018, 7 (08): : 4146 - 4155
  • [34] Chronic obstructive pulmonary disease and comorbidities' influence on mortality in non-small cell lung cancer patients
    Media, Ara Shwan
    Persson, Martin
    Tajhizi, Navid
    Weinreich, Ulla Moller
    ACTA ONCOLOGICA, 2019, 58 (08) : 1102 - 1106
  • [35] UPDATE IN NON SMALL-CELL LUNG CANCER STAGING
    Salgado, R. A.
    Snoeckx, A.
    Spinhoven, M.
    de Beeck, B. Op
    Corthouts, B.
    Parizel, P. M.
    JBR-BTR, 2013, 96 (03): : 118 - 122
  • [36] Quality of life in patients with non-small cell lung cancer
    Sarac, Sanja
    Milic, Rade
    Vasiljevic, Mira
    Sarac, Momir
    VOJNOSANITETSKI PREGLED, 2017, 74 (07) : 625 - 632
  • [37] Proteomic biomarkers of non-small cell lung cancer patients
    Baran, Kamila
    Brzezianska-Lasota, Ewa
    ADVANCES IN RESPIRATORY MEDICINE, 2021, 89 (04) : 419 - 426
  • [38] Radiotherapy for oligometastatic non-small cell lung cancer patients
    Levy, A.
    Roux, C.
    Mercier, O.
    Issard, J.
    Botticella, A.
    Barlesi, F.
    Le Pechoux, C.
    CANCER RADIOTHERAPIE, 2021, 25 (6-7): : 517 - 522
  • [39] Evaluation and Treatment of Patients with Non-Small Cell Lung Cancer
    Carr, Laurie L.
    Finigan, James H.
    Kern, Jeffrey A.
    MEDICAL CLINICS OF NORTH AMERICA, 2011, 95 (06) : 1041 - +
  • [40] Sleeve lobectomy for patients with non-small cell lung cancer
    Hanagiri, Takeshi
    Baba, Tetsuro
    Ichiki, Yoshinobu
    Yasuda, Manabu
    Sugaya, Masakazu
    Ono, Kenji
    Uramoto, Hidetaka
    Takenoyama, Mitsuhiro
    Yasumoto, Kosei
    INTERNATIONAL JOURNAL OF SURGERY, 2010, 8 (01) : 39 - 43